Johnson & Johnson

LogiPharma 2024 Playbook Highlights Why Real-Time Visibility & Data are Critical to Ensuring the Quality & Safety of New Medicines & Patient Therapies

Retrieved on: 
Tuesday, March 26, 2024
Automation, Temperature, Agility, Risk management, Research, Cold chain, Playbook, Johnson & Johnson, Artificial intelligence, Medtech, Fine chemical

The Playbook includes a detailed examination by Alex Guillen, Tive's Global SME in Life Sciences and Pharma, on the role of precise and timely supply chain data.

Key Points: 
  • The Playbook includes a detailed examination by Alex Guillen, Tive's Global SME in Life Sciences and Pharma, on the role of precise and timely supply chain data.
  • Guillen believes that ensuring the successful delivery and launch of dozens of new cell and gene therapies, as expected in 2024, is fundamentally dependent on the industry’s advancements in real-time supply chain visibility.
  • “An essential part of the conversation for pharma leaders today is how to address the critical challenges of modern therapy delivery," said Guillen.
  • To learn more about Tive and LogiPharma 2024, please visit www.tive.com and www.logipharmaeu.com .

Pharmaceutical CDMO Market Size, Share & Trends Analysis Report 2024: Increasing Demand for One-Stop-Shop CDMOs and Orphan Drug Discovery - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, CDMO, Growth, Patient, Knowledge, DSM-IV codes, Cancer, Commercial, Merck & Co., Oncology, Investment, Johnson & Johnson, Janssen, Drug development, API, Patent, Therapy, USD, Fine chemical

The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030.

Key Points: 
  • The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030.
  • A growing consumption of biopharmaceuticals, rising demand for advanced therapeutics, demand for orphan drug discovery, upsurge number of clinical trials and increasing demand for one-stop-shop CDMOS are anticipated to influence the global market positively.
  • As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes.
  • CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities.

Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Other Retail, Health, Retail, Pharmaceutical, Webcast, Conference, JNJ, Eastern Time Zone, Medtech, Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barclay Hotel, New York.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barclay Hotel, New York.
  • Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will represent the Company in a session scheduled at 11:00 am (Eastern Time).
  • The audio webcast replay will be available approximately 48-hrs after the webcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240408576293/en/

SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV

Retrieved on: 
Tuesday, April 9, 2024
Class Action Lawsuit, Professional Services, Legal, KSF, JNJ, Sale, Johnson & Johnson

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ).
  • Under the terms of the proposed transaction, shareholders of Shockwave will receive $335.00 in cash for each share of Shockwave that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

HealthQuest Capital Welcomes Ashley McEvoy to its Advisory Board

Retrieved on: 
Tuesday, April 9, 2024
Worldwide, Growth, CHOP, IAB, Executive, SAN, McEvoy, Hospital, Ecosystem, Johnson & Johnson, Procter & Gamble, Children's Hospital of Philadelphia, Medtech, Pharmaceutical industry

SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- HealthQuest Capital, a private asset firm that provides capital to transformative healthcare companies, today announced the addition of Ashley McEvoy to its Industry Advisory Board (IAB). McEvoy brings over 20 years of experience from Johnson & Johnson. This appointment will enhance HealthQuest Capital as a value-add investor for its ecosystem of portfolio companies by adding another complementary industry leader to drive progress within the healthcare space.

Key Points: 
  • SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- HealthQuest Capital , a private asset firm that provides capital to transformative healthcare companies, today announced the addition of Ashley McEvoy to its Industry Advisory Board (IAB).
  • This appointment will enhance HealthQuest Capital as a value-add investor for its ecosystem of portfolio companies by adding another complementary industry leader to drive progress within the healthcare space.
  • Ashley McEvoy is the former Executive Vice President and Worldwide Chairman of Johnson & Johnson's MedTech division, Ashley oversaw a vast organization with 60,000 global employees and revenue exceeding $30 billion.
  • "The addition of Ashley McEvoy strengthens our ability to identify and support innovative healthcare companies.

American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer

Retrieved on: 
Tuesday, April 9, 2024
Boston University, Lung cancer, Enzyme, Disease, Health equity, Partnership, Patient, Research, Doctor of Philosophy, Helpline, MD, Quality of life, Protein, Master of Science, Clinical trial, Partial, Johnson & Johnson, Interventional oncology, American Lung Association, UCLA, Charity Navigator, Cancer, Estate (law), Medical imaging

In a collaborative effort to end this devastating disease, the American Lung Association and LUNGevity Foundation have joined forces to invest $3 million over the next three years in research aimed at intercepting lung cancer – catching precancerous cells and blocking them from turning into cancer cells.

Key Points: 
  • In a collaborative effort to end this devastating disease, the American Lung Association and LUNGevity Foundation have joined forces to invest $3 million over the next three years in research aimed at intercepting lung cancer – catching precancerous cells and blocking them from turning into cancer cells.
  • The partnership builds upon previous collaborations, including research funded by American Lung Association, LUNGevity Foundation and Stand Up To Cancer, which has yielded significant findings in lung cancer interception.
  • Through initiatives like the American Lung Association Research Institute Accelerator Program and the LUNGevity Early Lung Cancer Center , this partnership aims to accelerate progress in lung cancer interception research and pave the way for personalized treatments for patients.
  • LUNGevity, the nation's leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.

Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization

Retrieved on: 
Monday, April 8, 2024
Cardiology, Abstract, Harvard Medical School, Warfarin, NACE, Rivaroxaban, Ventricular fibrillation, Data analysis, Risk, Patient, Stroke, Research, CSB, American College, Clinical trial, PCI, Bleeding, Johnson & Johnson, Percutaneous coronary intervention, Pharmaceutical industry

NEW BRUNSWICK, N.J., April 8, 2024 /PRNewswire/ -- Johnson & Johnson announced today a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO® (rivaroxaban) was associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of clinically significant bleeding [CSB] or major adverse cardiovascular event [MACE]) or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), a nonsurgical procedure designed to relieve narrowing or occlusion of the coronary artery.1,2 These data were featured in an oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta, Georgia (Abstract #906-04).

Key Points: 
  • "Despite advances in cardiovascular care, patients with nonvalvular AF continue to be at risk of potentially life-threatening cardiovascular events, especially older patients considered difficult to treat due to multiple factors, including age and co-morbidities," said C. Michael Gibson*, M.D., CEO, of the nonprofit Baim Institute and professor of Medicine, Harvard Medical School.
  • "A significant challenge in managing nonvalvular AF in older individuals undergoing PCI is determining a treatment that balances the prevention of stroke with the risk for bleeding.
  • Results from the PIONEER AF-PCI trial reinforce the need to continue to research this complex and fragile elderly patient population."
  • "With this new exploratory analysis at ACC.24, we're pleased to bring the latest research to healthcare providers that adds to the growing body of clinical evidence in older adults."

Engel & Völkers Continues Franchise Expansion in Florida with New Location in Trinity

Retrieved on: 
Monday, April 8, 2024
Professional, Science, University of North Georgia, Partnership, Acquisition, University, Ford, Insurance, Chemistry, Johnson & Johnson, Political science, Property management

NAPLES, Fla., April 8, 2024 /PRNewswire-PRWeb/ -- Engel & Völkers Florida today announced its latest franchise expansion into the vibrant market of Trinity, an affluent community in Pasco County. This strategic move comes as a result of the recent acquisition of license rights by distinguished entrepreneurs Tom Phanco and Clarence J. Butt. Their dynamic leadership extends beyond the real estate sector, as they integrate this residential arm seamlessly into their existing CTV Capital business—a multifaceted organization encompassing construction, commercial real estate, development, insurance, investment, mortgage, and property management. Engel & Völkers Trinity will initially operate from their temporary office at 18331 US-41 Suite 13 in Lutz, Florida inside the "Cowork of Lutz" building while their permanent office building is being built at 3047 Alachua Way in New Port Richey, Florida. A grand opening event is slated for the fourth quarter of 2024, upon completion of the shop build out.

Key Points: 
  • NAPLES, Fla., April 8, 2024 /PRNewswire-PRWeb/ -- Engel & Völkers Florida today announced its latest franchise expansion into the vibrant market of Trinity, an affluent community in Pasco County.
  • Engel & Völkers Trinity will initially operate from their temporary office at 18331 US-41 Suite 13 in Lutz, Florida inside the "Cowork of Lutz" building while their permanent office building is being built at 3047 Alachua Way in New Port Richey, Florida.
  • "Engel & Völkers emerged as the standout choice among competitors, and we are excited about forging a collaborative, enduring relationship.
  • "We are delighted to extend a warm welcome to Tom and CJ as franchise owners," said Peter Giese, CEO of Engel & Völkers Florida.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.